Skip to main content
SpringerLink
Log in

Doxazosin: long-acting α-blocker for hypertension and prostatic hypertrophy

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment fo High Blood Pressure (JNC V). Arch Intern Med 1993 Jan 25; 153: 154–83

    Article  Google Scholar 

  2. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993 Apr 10; 306: 983–7

    Article  PubMed  CAS  Google Scholar 

  3. Guidelines Sub-Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/ International Society of Hypertension meeting. J Hypertension 1993; 11(9): 905–18

    Article  Google Scholar 

  4. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995 Feb; 49(2): 295–320

    Article  PubMed  CAS  Google Scholar 

  5. British National Formulary No. 29. London: The Pharmaceutical Press, 1995

  6. Pfizer Inc. Doxazosin mesylate prescribing information. New York, NY, 1994

    Google Scholar 

  7. Management of drug-induced orthostatic hypotension. Drug Ther Perspect 1995 Jul 24; 6(2): 12–14

    Google Scholar 

  8. Drugs for hypertension. Med Lett Drug Ther 1995 May 26; 37(949): 45–50

    Google Scholar 

  9. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA 1993 Aug 11; 270(6): 713–24

    Article  PubMed  CAS  Google Scholar 

  10. Erley CM, Haefele U, Heyne N, et al. Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993 Jun; 21 (6 Pt 1): 810–5

    Article  PubMed  CAS  Google Scholar 

  11. Andersen JT. α1-Blockers vs 5α-reductase inhibitors in benign prostatic hyperplasia. Drug Aging 1995 May; 6(5): 388–96

    Article  CAS  Google Scholar 

  12. Chappie CR, Carter P, Christmas TJ, et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74; 50–6

    Article  Google Scholar 

  13. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995 Jul; 154: 105–9

    Article  PubMed  CAS  Google Scholar 

  14. Christensen MM, Holme JB, Rasmussen PC, et al. Doxazosin treatment in patients with prostatic obstruction. Scand J Urol Nephrol 1993; 27(1): 39–44

    Article  PubMed  CAS  Google Scholar 

  15. Peters DH, Sorkin EM. Finasteride: a review of its potential in the treatment of benign prostatic hypertrophy. 1993 Jul; 46(1): 177–208

    CAS  Google Scholar 

  16. Oesterling JE. Benign prostatic hypertrophy: medical and minimally invasive treatment options. N Engl J Med 1995 Jan 12; 332(2): 99–109

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doxazosin: long-acting α-blocker for hypertension and prostatic hypertrophy. Drugs Ther. Perspect 6, 5–8 (1995). https://doi.org/10.2165/00042310-199506050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199506050-00002

Keywords

Search

Navigation